A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

  • Muscle And Peripheral Nerve Disease
  • Spinal Muscular Atrophy (SMA)
Please note that the recruitment status of the trial at your site may differ.
Trial Status:

Not yet recruiting

This trial runs in
Cities
Trial Identifier:

NCT05861986 2023-504508-26-00 BN44620

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with SMA.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT05861986,BN44620,2023-504508-26-00 Trial Identifier
      risdiplam Treatments
      Muscular Atrophy, Spinal Condition
      Official Title

      A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy

      Eligibility Criteria

      All Gender
      ≥3 Months & ≤ 24 Months Age
      No Healthy Volunteers
      Inclusion Criteria
      • <2 years of age at the time of informed consent
      • Confirmed diagnosis of 5q-autosomal recessive SMA
      • Confirmed presence of two SMN2 gene copies
      • Administration of onasemnogene abeparvovec pre-symptomatically or post-symptomatically
      • Has received onasemnogene abeparvovec for SMA no less than 3 months, but not more than 7 months, prior to enrollment
      • Has, in the opinion of the investigator, not experienced clinically significant decline in function from the time of onasemnogene abeparvovec administration
      Exclusion Criteria
      • Treatment with investigational therapy prior to initiation of study treatment
      • Any unresolved standard-of-care laboratory abnormalities per the onasemnogene abeparvovec prescribing information
      • Concomitant or previous administration of a SMN2-targeting antisense oligonucleotide or SMN2 splicing modifier either in a clinical study or as part of medical care
      • Requiring invasive ventilation or tracheostomy
      • Requiring awake non-invasive ventilation or with awake hypoxemia (SaO2 <95%) with or without ventilator support
      • Presence of feeding tube and an OrSAT score of 0
      • Hospitalization for pulmonary event within the last 2 months, or any planned hospitalization at the time of screening
      • Any major illness requiring hospitalization within 1 month before the screening examination or any febrile illness within 1 week prior to screening and up to first dose administration.

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Spinal Muscular Atrophy (SMA)

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now